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Abstract
Background: Stressful life events have been shown to be associated with altered risk of various health consequences. The
aim of the present study was to investigate whether the emotional stress evoked by a prostate cancer diagnosis increases
the immediate risks of cardiovascular events and suicide.
Methods and Findings: We conducted a prospective cohort study by following all men in Sweden who were 30 y or older
(n=4,305,358) for a diagnosis of prostate cancer (n=168,584) and their subsequent occurrence of cardiovascular events and
suicide between January 1, 1961 and December 31, 2004. We used Poisson regression models to calculate relative risks (RRs)
and 95% confidence intervals (CIs) of cardiovascular events and suicide among men who had prostate cancer diagnosed
within 1 y to men without any cancer diagnosis. The risks of cardiovascular events and suicide were elevated during the first
year after prostate cancer diagnosis, particularly during the first week. Before 1987, the RR of fatal cardiovascular events was
11.2 (95% CI 10.4–12.1) during the first week and 1.9 (95% CI 1.9–2.0) during the first year after diagnosis. From 1987, the RR
for cardiovascular events, nonfatal and fatal combined, was 2.8 (95% CI 2.5–3.2) during the first week and 1.3 (95% CI 1.3–
1.3) during the first year after diagnosis. While the RR of cardiovascular events declined, the RR of suicide was stable over the
entire study period: 8.4 (95% CI 1.9–22.7) during the first week and 2.6 (95% CI 2.1–3.0) during the first year after diagnosis.
Men 54 y or younger at cancer diagnosis demonstrated the highest RRs of both cardiovascular events and suicide. A
limitation of the present study is the lack of tumor stage data, which precluded possibilities of investigating the potential
impact of the disease severity on the relationship between a recent diagnosis of prostate cancer and the risks of
cardiovascular events and suicide. In addition, we cannot exclude residual confounding as a possible explanation.
Conclusions: Men newly diagnosed with prostate cancer are at increased risks for cardiovascular events and suicide. Future
studies with detailed disease characteristic data are warranted.
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Growing evidence suggests that stressful events, such as the loss
of a child, war, or natural disasters, lead to an increased risk of
psychiatric hospitalizations [1] and cardiovascular morbidity [2]
with excess mortality [3–6]. Less is known about whether
emotional stress evoked by a cancer diagnosis increases the risks
of cardiovascular events and suicide, especially immediately after
diagnosis. Such possible consequences are of specific interest for
prostate cancer, which is now the most common malignancy
among men in westernized countries. Widespread prostate-specific
antigen (PSA)-testing has further entailed detection of large
numbers of men with uncertain survival benefit [7,8]. The
increased diagnostic activity calls for new knowledge on possible
stress-induced health effects that may be caused by the diagnosis.
Using the nationwide Swedish population-based registers, we
assessed whether men diagnosed with prostate cancer were at
increased risks of cardiovascular events and suicide during the year
after their diagnosis, in particular during the first weeks following
diagnosis.
Methods
We utilized the Swedish Census data that cover virtually all
residents in Sweden in 1960, 1970, 1980, and 1990. We identified
4,305,358 men, born in Sweden and at age 30 y or older between
January 1, 1961 and December 31, 2004. Using the national
registration number, an individually unique identifier of all
Swedish inhabitants, we were able to link Census information
with the Swedish Cancer, Causes of Death, and Inpatient
Registers and calculate incidence rates of cardiovascular events
and suicide. The study was approved by the Regional Ethics
Committee at the Karolinska Institutet.
Diagnosis of Prostate Cancer
By linkage to the nationwide Swedish Cancer Register, we
identified 173,701 men diagnosed with prostate cancer during the
study period. Reporting of cancers by clinicians and pathologists is
required by law since cancer registration began in 1958, and the
completeness of the register approaches 100% [9]. A total of 5,117
men diagnosed with prostate cancer first at autopsy were excluded,
leaving 168,584 men in the main analyses.
Assessment of Outcome
We obtained information on cardiovascular death and suicide
from the Causes of Death Register during the entire study period.
The essentially complete Causes of Death Register, established in
1952, includes the date of death and information on underlying and
contributory causes of death. Beginning for the year 1987, we were
also able to ascertain nonfatal cardiovascular events from linkage
with the Inpatient Register. Described in detail previously [10], the
Inpatient Register was initiated primarily for administrative
purposes in 1964, and its national coverage increased from 60%
in 1969, to 85% in 1983, and to 100% in 1987. The Register data
include the national registration number, up to eight discharge
diagnoses, and time of admission/discharge. Cardiovascular events
were registered as the underlying cause of death in the Causes of
Death Register or the main diagnosis in the Inpatient Register
according to the International Classification of Diseases; the 7th revision
(ICD-7) was used for coding diagnoses through 1968, the 8th
revision (ICD-8) between 1969 and 1986, the 9th revision (ICD-9)
between 1987 and 1996, and the 10th revision (ICD-10) after 1996.
Between 1961 and 1986, cardiovascular events were defined as
deaths with cardiovascular disease as the underlying cause
registered in the Causes of Death Register. With the completeness
of the Inpatient Register in 1987, cardiovascular events were
defined as hospitalizations with cardiovascular disease as the main
diagnosis (Inpatient Register) or deaths with cardiovascular disease
as the underlying cause of death (Causes of Death Register),
whichever came first. The detailed classification and codes for
cardiovascular events are shown in the Table S1. The complete-
ness and accuracy of the Inpatient Register are generally high.
The false negative rate of ischemic heart disease was estimated to
be 7% and the false positive rate was estimated to be 2% [11].
Deaths by suicide were classified in ICD-7 with codes E971–E979
and E9639, in ICD-8 and 9 with codes E950–959, and in ICD-10
with codes X60–X84 and Y870. Although some underreporting of
suicide may be expected, a validation study reviewing forensic data
indicates generally high accuracy of injury-related registration of
causes of death [12].
To examine the potential heterogeneity between fatal and
nonfatal cardiovascular events, we separately calculated the
relative risks (RRs) of hospitalization for cardiovascular diseases
and death from cardiovascular events among the prostate cancer
patients diagnosed in 1987–2004. We further utilized the Inpatient
Register to conduct stratified analyses based on previous
hospitalizations for psychiatric (ICD-9 codes 290–316; ICD-10
codes F00–F99) and cardiovascular disorders among men later
diagnosed with prostate cancer between 1990 and 2004. To
address the possibility that cardiovascular outcomes might be due
to the invasive procedures leading to the diagnosis of prostate
cancer, we also performed several sensitivity analyses by excluding
patients that were diagnosed at transurethral resection of the
prostate, with any hospitalization during the month before
diagnosis, or treated with radical prostatectomy after diagnosis,
respectively.
Follow-up
Follow-up of the study participants started from January 1, 1961
or from their 30th birthday, whichever came earlier. For those
who did not develop prostate cancer, the follow-up ended at the
date of diagnosis of any other malignancy, death, emigration, or
December 31, 2004, whichever occurred first; accumulated
person-time was defined as unexposed person-time. For men
diagnosed with prostate cancer, the follow-up ended 1 y after the
diagnosis, occurrence of cardiovascular events or suicide, other
death, emigration out of Sweden, or December 31, 2004,
whichever came first; accumulated person-time defined as exposed
person-time. Men diagnosed with prostate cancer contributed
unexposed person-time before the date of diagnosis (as recorded in
the Cancer Register) and exposed person-time thereafter.
To examine the RRs of suicide and cardiovascular events
beyond the first year after prostate cancer diagnosis, we performed
additional analysis by extending the follow-up among prostate
cancer patients beyond the first year time window until the
occurrence of cardiovascular events or suicide, other death,
emigration, or end of study.
Statistical Analyses
We used log-linear Poisson regression models to calculate the
overall RRs and 95% confidence intervals (95% CIs) of cardiovas-
cular events and suicide, as the ratio of the corresponding incidence
rates among the newly diagnosed prostate cancer patients to the
incidence rates among the cancer-free men. We adjusted for
calendar period and age in all statistical models. We compared the
RRs within strata of age, calendar year of follow-up, and time since
diagnosis (week 1, weeks 2–4, weeks 5–26, and weeks 27–52).
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suicide by marital status, educational level (as registered in the
Swedish Education Register, which contains educational informa-
tion of Swedish residents alive in 1985 and onward), and history of
psychiatric hospitalization. We also compared RRs of cardiovascu-
lar events among prostate cancer patients diagnosed from 1990
through 2004 after stratification by history of cardiovascular
hospitalization. The significance of potential interactions between
the above variables and prostate cancer diagnosis was tested by
adding a term of one specific variable multiplying prostate cancer
diagnosis. Pearson’s x
2 test was used to check the goodness of fit of
the models. Overdispersion was corrected by using the deviance
factor of Pearson’s statistic if any.
The overall RRs of cardiovascular events and suicide were also
calculated for follow-up beyond 1 y after diagnosis among the
newly diagnosed prostate cancer patients. For comparison, we also
calculated the RR of hospitalization for two other common
conditions in this population (osteoarthritis [ICD-9: 715A–D,
715W, 715X; ICD-10: M15–19] and diabetes [ICD-9: 250; ICD-
10: E10–14]) following the diagnosis of prostate cancer. For the
statistical analyses we used SAS version 9.1 software (SAS
Institute, Inc.).
Results
Between 1961 and 2004, a total of 4,305,358 men were followed
with over 90 million unexposed person-years and approximately
150,000 person-years among men newly diagnosed with prostate
cancer. The mean age at diagnosis of prostate cancer was 73.4 y
(range 31.6–102.5 y). Of 168,584 men diagnosed with prostate
cancer, 10,126 (6%) experienced a cardiovascular event during the
year following diagnosis and 136 (0.08%) committed suicide.
Cardiovascular Events
In 1961–1986, 4,631 of the 71,818 prostate cancer patients died
from a cardiovascular event within 1 y after diagnosis; the risk for
a fatal cardiovascular event among the prostate cancer patients
was 1.9 times higher than among the cancer-free men (Table 1).
The RR was highest during the first week after diagnosis (RR
11.2), decreased gradually thereafter, but remained elevated
throughout the first year. The excess risk was greatest among
men 54 y or younger at prostate cancer diagnosis (RR 4.8) but still
elevated among men 75 y or older (RR 1.7). The RR tended to
decrease with calendar time, from RR of 2.9 in 1961–1970 to RR
of 1.3 in 1981–1986. The RR of fatal cardiovascular events was
1.1 (95% CI 1.1–1.1) beyond the first year of follow-up in 1961–
1986.
In 1987–2004, a total of 5,495 cardiovascular events were
observed among the prostate cancer patients during the first year
after diagnosis. The overall risk of fatal and nonfatal cardiovas-
cular events was elevated among the prostate cancer patients (RR
1.3), especially during the first week after diagnosis (RR 2.8)
(Table 2). As noted in 1961–1986, although the RR was strongest
during the first week, it remained statistically significantly elevated
Table 1. Incidence rates and RRs of cardiovascular events during the first year after the diagnosis of prostate cancer in Sweden,
1961–1986.
Category Cardiovascular Events IR per 1,000 Person-years RR
a (95% CI)
Totals Cancer-free 564,740 10.4 1.0
PCa 4,631 77.1 1.9 (1.9–2.0)
Time since diagnosis (wk)
1 710 457.9 11.2 (10.4–12.1)
2–4 848 215.6 5.4 (5.0–5.8)
5–26 1,729 65.0 1.6 (1.6–1.7)
27–52 1,344 48.0 1.2 (1.1–1.3)
Age (y)
#54 Cancer-free 57,423 1.6 1.0
PCa 64 20.2 4.8 (3.7–6.0)
55–64 Cancer-free 121,544 12.0 1.0
PCa 555 35.2 2.7 (2.5–2.9)
65–74 Cancer-free 200,113 33.7 1.0
PCa 2,050 72.6 2.1 (2.0–2.2)
$75 Cancer-free 185,660 94.7 1.0
PCa 1,962 151.9 1.7 (1.6–1.8)
Calendar year of follow-up
1961–1970 Cancer-free 199,397 9.8 1.0
PCa 1,822 116.1 2.9 (2.8–3.0)
1971–1980 Cancer-free 228,847 10.9 1.0
PCa 1,810 71.7 1.8 (1.7–1.9)
1981–1986 Cancer-free 136,496 10.5 1.0
PCa 999 52.2 1.3 (1.2–1.4)
aAdjusted for age at follow-up (5-y group between 30 and 84, and $85 y) and calendar year (1-y group between 1961 and 1986).
IR, incidence rate; PCa, prostate cancer.
doi:10.1371/journal.pmed.1000197.t001
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greatest among men 54 y or younger at cancer diagnosis (RR 1.5).
The magnitude of the RR declined over the calendar time and
reached a plateau at around 20%–30% since the 1980s. Beyond
the first year after diagnosis, the RR of overall cardiovascular
events was 1.2 (95% CI 1.2–1.2) in 1987–2004.
Among patients diagnosed in 1987–2004, the RR of hospital-
ization for cardiovascular diseases was 1.3 (95% CI 1.3–1.4)
during the first year and 2.4 (95% CI 2.1–2.7) during the first week
after diagnosis; the corresponding RRs for cardiovascular death
were 1.1 (95% CI 1.1–1.1) during the first year and 3.7 (95% CI
3.2–4.2) during the first week.
Our data further suggest that men without a history of
cardiovascular disease before the diagnosis of prostate cancer
may have a higher RR of cardiovascular events immediately after
a prostate cancer diagnosis compared to men with a history of
cardiovascular disease (Table 3). Among men without a history of
cardiovascular disease, prostate cancer diagnosis induced a 5-fold
risk of cardiovascular event (fatal and nonfatal combined) in the
first week (RR 4.8) and a 3-fold risk in the first 4 wk (RR 2.9) after
prostate cancer diagnosis. Among men with previous cardiovas-
cular history, the first-week RR was 2.8 and the first-4-wk RR was
1.8. After overdispersion correction, a borderline significant
interaction between a history of cardiovascular disease and
prostate cancer diagnosis was noted for the first-4-wk RR of
overall cardiovascular events (p=0.08) although not for the first
week (p=0.22).
To assess whether the higher risk for cardiovascular events after
prostate cancer diagnosis was due to better cancer detection
among men with previous heart disease or deteriorating health in
general, we excluded all men with any hospitalization during the
month before prostate cancer diagnosis. This restriction did not
alter the results (unpublished data). Similarly, exclusion of men
with radical prostatectomy or transurethral resection of the
prostate did not affect the RR estimates (unpublished data).
Finally, men diagnosed with prostate cancer did not show an
increased risk of being hospitalized for osteoarthritis (RR 1.0; 95%
CI 0.8–1.4) or diabetes (RR 0.8; 95% CI 0.5–1.5) during the first
month after their diagnosis.
Suicide
A total of 136 (0.08%) prostate cancer patients committed
suicide within 1 y after cancer diagnosis; the risk for suicide was
more than doubled among prostate cancer patients compared to
the cancer-free men (RR 2.6) (Table 4). The excess risk was
highest during the first week after diagnosis (RR 8.4) and
decreased with time since diagnosis, but was still clearly significant
by the end of the first year (RR 1.9). The RR for suicide after
diagnosis was 4.6 among men 54 y or younger, approximately
twice that of older age groups. The risk of suicide remained more
than doubled throughout the entire study period and was not
modified by educational level (p for interaction=0.88), marital
status (p for interaction=0.20), or prior psychiatric hospitalization
(p for interaction=0.26) (unpublished data). The risk of suicide
Table 2. Incidence rates and RRs of cardiovascular events during the first year after the diagnosis of prostate cancer in Sweden,
1987–2004.
Category Cardiovascular Events IR per 1,000 Person-years RR
a (95% CI)
Totals Cancer-free 763,321 21.3 1.0
PCa 5,495 82.6 1.3 (1.3–1.3)
Time since diagnosis (wk)
1 279 176.5 2.8 (2.5–3.2)
2–4 429 104.2 1.7 (1.5–1.8)
5–26 2,321 79.8 1.3 (1.2–1.3)
27–52 2,466 77.7 1.2 (1.2–1.2)
Age (y)
#54 Cancer-free 184,128 7.1 1.0
PCa 128 23.2 1.5 (1.3–1.8)
55–64 Cancer-free 177,070 33.9 1.0
PCa 961 50.7 1.5 (1.4–1.6)
65–74 Cancer-free 232,084 66.7 1.0
PCa 2,433 86.2 1.3 (1.2–1.4)
$75 Cancer-free 170,039 122.0 1.0
PCa 1,973 142.5 1.2 (1.1–1.2)
Calendar year of follow-up
1987–1992 Cancer-free 338,670 27.4 1.0
PCa 2,195 111.2 1.3 (1.3–1.4)
1993–1998 Cancer-free 236,947 20.1 1.0
PCa 1,748 87.9 1.3 (1.3–1.4)
1999–2004 Cancer-free 187,704 16.0 1.0
PCa 1,552 57.7 1.2 (1.2–1.3)
aAdjusted for age at follow-up (5-y group between 30 and 84, and $85 y) and calendar year (1-y group between 1987 and 2004).
IR, incidence rate; PCa, prostate cancer.
doi:10.1371/journal.pmed.1000197.t002
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Category Suicide IR per 1,000 person-years RR
a (95% CI)
Totals Cancer-free 31,822 0.3 1.0
PCa 136 0.9 2.6 (2.1–3.0)
Time since diagnosis (wk)
1 11 3.0 8.4 (1.9–22.7)
2–4 9 1.0 2.7 (1.3–4.8)
5–26 69 1.0 3.0 (2.3–3.7)
27–52 47 0.7 1.9 (1.4–2.4)
Age at follow-up (y)
#54 Cancer-free 20,687 0.3 1.0
PCa 14 1.5 4.6 (2.6–7.4)
55–64 Cancer-free 5,524 0.3 1.0
PCa 23 0.6 1.9 (1.2–2.8)
65–74 Cancer-free 3,862 0.4 1.0
PCa 62 0.9 2.6 (2.0–3.4)
$75 Cancer-free 1,749 0.4 1.0
PCa 37 1.1 2.5 (1.8–3.4)
Calendar year of follow-up
1961–1970 Cancer-free 7,818 0.4 1.0
PCa 24 1.5 3.4 (2.2–5.0)
1971–1980 Cancer-free 8,174 0.4 1.0
PCa 24 1.0 2.3 (1.6–3.1)
1981–1990 Cancer-free 7,452 0.3 1.0
PCa 37 1.1 2.8 (1.7–4.2)
1991–2004 Cancer-free 8,378 0.3 1.0
PCa 51 0.7 2.3 (1.8–2.8)
aAdjusted for age at follow-up (5-y group between 30 and 84, and $85 y) and calendar year (5-y group between 1961–2004).
IR, incidence rate; PCa, prostate cancer.
doi:10.1371/journal.pmed.1000197.t004
Table 3. RRs of death from specific cardiovascular events during the first week and the first 4 wk after the diagnosis of prostate
cancer by history of cardiovascular disease in Sweden, 1990–2004.
Category All Cardiovascular Events
Myocardial
Infarction Embolism/Thrombosis
Other Heart
Disease
Acute Cerebro-
Vascular Events
n RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Men without a history of cardiovascular events
Cancer-free 51,378 1.0 1.0 1.0 1.0 1.0
PCa, 1 wk after diagnosis 38 4.8 (3.2–6.9) 4.8 (2.8–7.5) 18.3 (7.1–37.5) 5.9 (1.9–14.9) —
PCa, 4 wk after diagnosis 84 2.9 (2.2–3.7) 2.9 (2.0–3.9) 10.1 (4.3–19.9) 2.7 (1.2–5.7) 3.5 (1.3–7.1)
Men with a history of cardiovascular events
Cancer-free 204,627 1.0 1.0 1.0 1.0 1.0
PCa, 1 wk after diagnosis 116 2.8 (2.0–3.8) 3.9 (2.9–5.1) 7.9 (3.6–14.7) 4.8 (2.4–8.3) 1.3 (0.4–3.3)
PCa, 4 wk after diagnosis 265 1.8 (1.4–2.2) 2.1 (1.4–2.2) 4.0 (2.0–7.0) 2.4 (1.4–3.8) 1.1 (0.6–1.9)
Analysis restricted to patients diagnosed since January 1, 1990 (3 y after the nationwide completion of the Inpatient Register) and adjusted for age at follow-up (5-y
group between 30 and 84, and $85 y) as well as calendar year (5-y group between 1990–2004).
PCa, prostate cancer.
doi:10.1371/journal.pmed.1000197.t003
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CI 1.6–2.0) during the entire study period.
Discussion
In this large population-based study, men newly diagnosed with
prostate cancer were at higher risks of cardiovascular events and
suicide. The excess risks were highest during the first week after
diagnosis, suggesting that the stress of diagnosis itself rather than
subsequent factors such as hormonal treatment or operations plays
a role. Also, we observed the highest excess risk of cardiovascular
events among younger men, for whom the potential loss of years to
live, of sexual potency, and of other aspects of life might be of
greater concern than in older men.
We propose that the emotional stress associated with the
diagnosis of prostate cancer leads to higher risks of cardiovascular
morbidity and suicide. To our knowledge, no study has previously
explored whether cardiovascular morbidity increases immediately
after the diagnosis of prostate cancer. Several lines of evidence
support the notion that emotionally stressful life events may lead to
stunning or altered function of the heart. Wittstein and colleagues
described stress-related left ventricular dysfunction in 13 individ-
uals who had experienced a stressful event [13]; the authors found
an exaggerated sympathetic stimulation to be responsible for this
reversible condition. Epidemiological studies have found further
manifestations of cardiovascular morbidity due to emotional stress.
Increased risk of myocardial infarction was documented following
the Athens earthquake in 1983 [3]. Bereaved parents have been
reported to have increased risk for both fatal and nonfatal
myocardial infarction [2], and more recently emotional stress
brought on by viewing a World cup soccer match was reported to
raise the risk for cardiovascular morbidity and mortality [14]. Our
data suggest that being diagnosed with prostate cancer may also
serve as a stressor of substantial weight, resulting in severe health
outcomes.
Although a statistically significant excess risk of cardiovas-
cular events during the year after prostate cancer diagnosis was
observed over the entire study period in our data, the
magnitude of the excess risk declined from 2.9 in the 1960s
toward 1.3 in 1980s and stayed stable onwards. The underlying
reason for the declination before 1980s is unclear. The
decreasing incidence of advanced prostate cancer over
calendar time as well as the increasing awareness of prostate
cancer in the general population may reduce the intensity of
emotional stress experienced by men diagnosed with prostate
cancer. However, the fact that the RR of suicide remained
relatively stable during the entire study period challenges this
explanation. Furthermore, the RR of cardiovascular events
dropped already in the early 1980s, which was before the
advent of PSA screening and many men were still diagnosed
with advanced disease, and stayed stable thereafter. A more
probable explanation for the decrease in the immediate RR of
cardiovascular events, especially the fatal events, after prostate
cancer diagnosis may be the closer contact with medical
surveillance or increased use of cardiovascular therapy; for
example, beta blockers may have provided protection against
cardiovascular events particularly in individuals exposed to
emotionally stressful events. In line with this reasoning, we
noted that prostate cancer patients with a history of
cardiovascular disease had a lower RR of cardiovascular
events, compared to patients without a history of cardiovas-
cular disease.
Although the absolute risk was small, our findings indicate
that prostate cancer patients are at considerably higher risk of
suicide, particularly during the first week after diagnosis. The
magnitude of the RR for suicide stayed relatively consistent
during the entire study period. Earlier studies have shown that
stressful life events including loss of a child increase the risks of
both psychiatric hospitalizations [1] and unnatural deaths [5].
Studies have also reported an increased risk of suicide among
patients with cancer of the breast [15], prostate [16], and other
sites [17–19]; few of them indicate that the risk may be highest
during the first months or years after diagnosis [18,19]. Our
observation that the excess risk was most prominent during the
first week after prostate cancer diagnosis has, to our
knowledge, not been reported previously. Possible mechanisms
remain unknown but the emotional shock caused by the
diagnosis, anxiety for the pending choice of treatment,
together with emotional isolation, may explain the impulsive
action. About 20% of the prostate cancer patients were
reported as having no one to confide in [20].
Strengths of our study include the large size, population-based
design, prospective data collection, and complete follow-up, with
minimal potential for bias or differential misclassification of
exposure and outcome. There are several limitations. The date
of diagnosis assessed from the Cancer Register represents the date
of the pathology diagnosis; thus, the patients may be informed
days or even weeks later after the registered time of diagnosis.
While this would not alter the number of events, it might influence
the risk estimates and chiefly entail underestimation of the true
excess risk during the first week and overestimation of the excess
risk during subsequent weeks. Based on the register data, our study
lacked information on clinical features including tumor stage at
diagnosis. The level of stress experienced by the patient at
diagnosis, and correspondingly the risk of immediate hazardous
outcomes, may vary with stage (or chances of cure) [21], and we
believe the associations with immediate adverse health effects
could be stronger among patients with advanced stage disease.
The lack of stage information does not affect, however, the validity
of our findings. Exclusion of men that were hospitalized for any
condition during the month before diagnosis did not alter our
results—thus alleviating concerns of reverse causality.
Furthermore, analyses excluding patients undergoing transure-
thral resection of the prostate or radical prostatectomy did not
attenuate our RR estimates. Although the true number of suicides
is difficult to assess even after close scrutiny of all available
information [12], we lack evidence that misclassification of death
would differ between men with and without a prostate cancer
diagnosis. Given the observational design of the study, influence of
unknown or unmeasured confounders cannot be ruled out.
While the incidence of prostate cancer has doubled over the last
30 y in Sweden as well as in other western countries, the mortality
by prostate cancer remained unchanged [22] and whether PSA
screening does more good than harm is hotly debated [7,8,23].
Our finding of an association between prostate cancer diagnosis
and the increased occurrence of sudden cardiovascular events and
suicide adds new knowledge to be weighed into this challenging
issue. Limited to prostate cancer patients, our findings cannot be
readily generalized to other cancer types or to women. The
declining excess risk of cardiovascular events after prostate cancer
diagnosis over calendar time shows how multiple factors that vary
across time and cultures, for example, medical advancements and
degree of stress at a cancer diagnosis, modify the risk of hazardous
outcomes after a prostate cancer diagnosis. Thus, alertness in
clinical care and careful monitoring of the psychological health of
newly diagnosed prostate cancer patients is needed as well as
development of strategies to reduce the risk of adverse health
outcomes after diagnosis.
CVD/Suicide Risk in Prostate Cancer Diagnosis
PLoS Medicine | www.plosmedicine.org 6 December 2009 | Volume 6 | Issue 12 | e1000197In summary, our data suggest that men who receive a prostate
cancer diagnosis are immediately at increased risks of cardiovas-
cular events and suicide. The risks are highest during the first week
after diagnosis and young men seem to be most vulnerable. These
unrecognized consequences of a prostate cancer diagnosis deserve
the attention of health professionals who take care of the
increasing number of men that are diagnosed with this disease.
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Background. Prostate cancer—a type of tumor that
develops in a walnut-sized structure in the male
reproductive system—is the commonest cancer (excluding
skin cancer) among men in developed countries. In the USA
and the UK, for example, one in six men will develop prostate
cancer during their lifetime. Most prostate cancers develop
in elderly men and, because these tumors usually grow
relatively slowly, many men die with prostate cancer rather
than as a result of it. Nevertheless, some prostate cancers are
fast-growing and aggressive and prostate cancer is the
second leading cause of cancer-related death among men.
The symptoms of prostate cancer include problems urinating
and excessive urination during the night. Nowadays,
however, most prostate cancers are detected before they
produce any symptoms by measuring the amount of a
protein called the prostate-specific antigen (PSA) in the
blood.
Why Was This Study Done? Widespread PSA screening
was introduced 20 years ago in the hope that early detection
of prostate cancer would save lives. But, although many
more prostate cancers are detected nowadays, the number
of prostate cancer deaths has not changed significantly.
Experts are divided, therefore, about whether the potential
benefits of PSA screening outweigh its risks. Treatments for
prostate cancer (for example, surgical removal of the
prostate) may be more effective if they are started early
but they can cause impotence and urinary incontinence, so
should men be treated whose cancer might otherwise never
affect their health? In addition, receiving a diagnosis of
prostate cancer is stressful and there is growing evidence
that stressful life events can increase an individual’s risk of
becoming ill or dying from a heart attack, stroke, or other
‘‘cardiovascular’’ events and of becoming mentally ill. In this
study, therefore, the researchers investigate whether men
diagnosed with prostate cancer in Sweden have increased
risks of cardiovascular events and suicide during the first
week and first year after their diagnosis.
What Did the Researchers Do and Find? The researchers
identified nearly 170, 000 men diagnosed with prostate
cancer between 1961 and 2004 among Swedish men aged
30 years or older by searching the Swedish Cancer Register.
They obtained information on subsequent fatal and nonfatal
cardiovascular events and suicides from the Causes of Death
Register and the Inpatient Register (in Sweden, everyone has
a unique national registration number that facilitates
searches of different health-related Registers). Before 1987,
men with prostate cancer were about 11 times as likely to
have a fatal cardiovascular event during the first week after
their diagnosis as men without prostate cancer; during the
first year after their diagnosis, men with prostate cancer were
nearly twice as likely to have a cardiovascular event as men
without prostate cancer (a relative risk of 1.9). From 1987, the
relative risk of combined fatal and nonfatal cardiovascular
events associated with a diagnosis of prostate cancer was 2.8
during the first week and 1.3 during the first year after
diagnosis. The relative risk of suicide associated with a
diagnosis of prostate cancer was 8.4 during the first week
and 2.6 during the first year after diagnosis throughout the
study period. Finally, men younger than 54 years at diagnosis
had higher relative risks of both cardiovascular events and
suicide.
What Do These Findings Mean? These findings suggest
that men newly diagnosed with prostate cancer have an
increased risk of cardiovascular events and suicide. Because
there is no information on tumor size or aggressiveness in
the Cancer Register, the researchers could not look at the
relationship between disease severity and the likelihood of a
cardiovascular event or suicide. Furthermore, because of the
study design, men who received a diagnosis of prostate
cancer may have had additional characteristics in common
that contributed to their increased risk of cardiovascular
events and suicide. Nevertheless, these findings strongly
suggest that the stress of the diagnosis itself rather than any
subsequent treatment has deleterious effects on the health
of men receiving a diagnosis of prostate cancer. Thus,
strategies should be developed to reduce the risks of
cardiovascular events and suicide—increased clinical and
psychological monitoring—after a diagnosis of prostate
cancer, particularly among young men, and this new
information should be considered in the ongoing debate
about the risks and benefits of PSA screening.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000197.
N The US National Cancer Institute provides information on
all aspects of prostate cancer, (in English and Spanish)
N The US Centers for Disease Control and Prevention
provides information on prostate cancer, including Pros-
tate Cancer Screening, A Decision Guide (some information
in multiple languages)
N The UK National Health Service Choices Web site provides
detailed information on prostate cancer
N The UK-based Samaritans charity provides confidential
nonjudgmental emotional support, 24 hours a day, for
people who are experiencing feelings of distress or
despair, including those which could lead to suicide
N Outside the UK, Befrienders provides information on help
lines for those experiencing distress
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